Combined Research

 
Stock Quotes for Combined Research top ^
  • Industry: Rubber & Plastics
  • Sector: Consumer Cyclical
  • Stock Style: Small Value
Sign-up for n0z investment picks

 
News Articles for Combined Research top ^
DALLAS, April 21, 2014 (GLOBE NEWSWIRE) -- PMFG, Inc. (the "Company") (Nasdaq:PMFG) today announced that it has been awarded two contracts with a combined value of greater than $9 million.
Sign-up for PMFG, Inc. (Parent of Peerless Mfg. Co.) Awarded Two New Material Orders With a Combined Value of Over $9 Million investment picks
2014/4/29
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0942497001&sourceType=1 http://media3.marketwire.com/logos/20120224-merc_reg.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Mercator Minerals Provides Update on Combination with Intergeo investment picks
Company Announcement CHMP recommends marketing authorization for Arzerra in combination with chlorambucil or bendamustine for patients with CLL who have not received prior therapy and are not eligible for fludarabine-based therapy Final decision from European Commission expected in the coming months COPENHAGEN, Denmark, May 23, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation to the terms of the marketing authorization for Arzerra(tm) for a new indication in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Sign-up for GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy investment picks
CHARLOTTE, N.C. and DUBLIN , April 29, 2014 /PRNewswire/ -- Chiquita Brands International, Inc. (NYSE: CQB) (" Chiquita ") and Fyffes plc (ESM: FFY ID: AIM: FFY LN) (" Fyffes ") today announced that ChiquitaFyffes Limited ("ChiquitaFyffes") has filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 in connection with the proposed combination of Chiquita and Fyffes, which included a preliminary proxy statement of Chiquita (the "Form S-4") and a draft of the Irish scheme circular of Fyffes.
Sign-up for ChiquitaFyffes Files Registration Statement on Form S-4 in Connection with the Proposed Combination of Chiquita and Fyffes investment picks
CHARLOTTE, N.C. and DUBLIN , April 29, 2014 /PRNewswire/ -- Chiquita Brands International, Inc. (NYSE: CQB) (" Chiquita ") and Fyffes plc (ESM: FFY ID: AIM: FFY LN) (" Fyffes ") today announced that they have revised certain of the conditions to consummation of their proposed combination transaction.
Sign-up for Chiquita and Fyffes Revise Certain of the Conditions to Consummation of Their Proposed Combination Transaction Confirming the Jurisdiction of the European Commission to Review the Transaction investment picks
BERKELEY HEIGHTS, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines.
Sign-up for Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML investment picks
CONWAY, Ark., April 17, 2014 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (Nasdaq:HOMB) ("Home" or "the Company"), parent company of Centennial Bank ("Centennial"), and Florida Traditions Bank ("Traditions"), today announced they have entered into a non-binding letter of intent for the Company to acquire all of the outstanding shares of Traditions, which will be merged into Centennial.
Sign-up for Home BancShares, Inc. and Florida Traditions Bank Announce Pending Business Combination investment picks
Company Announcement Arzerra now approved for use in previously untreated patients for whom fludarabine-based therapy is considered inappropriate Approval based on Phase III data from study with ofatumumab + chlorambucil COPENHAGEN, Denmark, April 17, 2014 (GLOBE NEWSWIRE) -- Copenhagen, Denmark; April 17, 2014 - GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra (r) (ofatumumab), a CD20-directed monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
Sign-up for GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate investment picks
PLACERVILLE, CA , May 8, 2014 /PRNewswire/ - iMD Companies, Inc. (OTC:ICBU) The company announced today that several key strategic options were solidified and scripted at its National Sales Conference held in Sacramento, CA during the last week of April.
Sign-up for iMD Companies Inc., Subsidiaries Synergistically Combine Sales Forces to Meet Demand for Hydroponics Market investment picks
By Michael Calia Mondelez International Inc. on Wednesday said it plans to combine its coffee portfolio with D.E. Master Blenders 1753 B.V. to create a new coffee company, as part of a $3.5 billion restructuring program.
Sign-up for UPDATE: Mondelez, D.E. Master Blenders combine coffee companies investment picks
By Michael Calia Mondelez International Inc. on Wednesday said it plans to combine its coffee portfolio with D.E. Master Blenders 1753 B.V. to create a new coffee company, as part of a $3.5 billion restructuring program.
Sign-up for Mondelez, D.E. Master Blenders combine coffee companies investment picks
http://media.marketwire.com/attachments/201405/75480_gag.jpg http://media.marketwire.com/attachments/201405/75481_briley.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1116894&ProfileId=051205&sourceType=1 WOODLAND HILLS, CA and LOS ANGELES, CA --
Sign-up for Great American Group and B. Riley & Co. Announce Definitive Agreement to Combine investment picks
Company Announcement No statistically significant difference in progression free survival in ofatumumab plus chemotherapy treatment arm compared to rituximab plus chemotherapy Detailed data will be presented at an upcoming medical conference LONDON and COPENHAGEN, Denmark, May 19, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the Phase III study (ORCHARRD) of ofatumumab (Arzerra(tm)) plus chemotherapy versus rituximab plus chemotherapy to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint as there was no statistically significant difference in progression free survival (PFS) between the treatment arms.
Sign-up for GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma investment picks
2014/4/28
Pfizer Inc. will hold analyst and investor calls to discuss its continuing interest in a possible merger transaction with AstraZeneca Plc.
Sign-up for Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Possible Combination With AstraZeneca investment picks
By David Marsh, MarketWatch A U.S. pharmaceuticals company renowned for making drugs with revitalizing qualities appears to be having a similar impact on sterling.
Sign-up for UPDATE: Pfizer, AstraZeneca and the pound -- a heady combination investment picks
BEIJING , May 5, 2014 /PRNewswire-FirstCall/ -- Launched by the China Fruit Brand Promotion Association and China Fruits Corporation (OTC: CHFR) (" China Fruits " or "the Company"), the final competition and award ceremony of Taina ® First Nationwide Fruit-themed beauty contest took place at the China National Convention Center (CNCC). After one and half months of preliminary competitions, ten beauties stood out through online mass-selection and semifinal and final presentations, and became ten fruit ambassadors.
Sign-up for First Taina® Miss Fruit National Beauty Pageant Finalized, the Combination of Beauty and Fruit Leads New Healthy Fashion Trend investment picks
BERKELEY HEIGHTS, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the Company's lead clinical candidate.
Sign-up for New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments investment picks

 
Article Quotes for Combined Research top ^
2010/08/31
The Combine feature in Morningstar.com's Portfolio Manager tool allows investors to create a streamlined view of their assets to help accomplish specific goals.
Sign-up for Optimize Your Portfolios by 'Combining' Them investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Combined Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Columbia Banking System  |  Next: Cominar Real Estate Investment